期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 5, 页码 2837-2842出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.8b01567
关键词
-
Starting from a previously reported ROR gamma inhibitor (1), successive efforts to improve in vivo potency were continued. Introduction of metabolically beneficial motifs in conjunction with scaffold hopping was examined, resulting in discovery of the second generation ROR gamma inhibitor composed of a 4-(isoxazol-3-yl)butanoic acid scaffold (24). Compound 24 achieved a 10-fold improvement in in vivo potency in a mouse CD3 challenge model along with significant anti-inflammatory effects in a mouse dermatitis model.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据